Neuren Pharmaceuticals Limited (NURPF)
USD 7.34
(-3.8%)
USD 7.34
(-3.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 172.49 Million AUD | 12505.23% |
| 2022 | -1.6 Million AUD | 85.96% |
| 2021 | -11.43 Million AUD | -20.0% |
| 2020 | -9.53 Million AUD | 17.65% |
| 2019 | -11.57 Million AUD | -318.77% |
| 2018 | 5.29 Million AUD | 184.32% |
| 2017 | -6.27 Million AUD | 58.84% |
| 2016 | -15.24 Million AUD | 12.08% |
| 2015 | -17.34 Million AUD | -37.4% |
| 2014 | -12.62 Million AUD | -33.57% |
| 2013 | -9.44 Million AUD | 0.3% |
| 2012 | -9.47 Million AUD | -100.18% |
| 2011 | -4.73 Million AUD | 5.09% |
| 2010 | -4.98 Million AUD | -3904.59% |
| 2009 | 131.13 Thousand AUD | 101.39% |
| 2008 | -9.43 Million AUD | 21.98% |
| 2007 | -12.09 Million AUD | 0.71% |
| 2006 | -12.17 Million AUD | -7.87% |
| 2005 | -11.28 Million AUD | -60.84% |
| 2004 | -7.01 Million AUD | -402.28% |
| 2003 | 2.32 Million AUD | 45.47% |
| 2002 | 1.59 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.91 Million AUD | -104.58% |
| 2024 Q2 | -6.91 Million AUD | 0.0% |
| 2023 Q1 | 24.07 Million AUD | 319.29% |
| 2023 Q4 | 151.08 Million AUD | 99.98% |
| 2023 FY | 199.22 Million AUD | 12505.23% |
| 2023 Q3 | 75.55 Million AUD | 56.93% |
| 2023 Q2 | 48.14 Million AUD | 100.0% |
| 2022 Q2 | -7.33 Million AUD | -100.0% |
| 2022 Q1 | -3.66 Million AUD | -13.51% |
| 2022 Q3 | 3.3 Million AUD | 145.01% |
| 2022 Q4 | 5.74 Million AUD | 73.84% |
| 2022 FY | -1.6 Million AUD | 85.96% |
| 2021 Q3 | -17.5 Thousand AUD | 99.79% |
| 2021 FY | -11.43 Million AUD | -20.0% |
| 2021 Q4 | -3.23 Million AUD | -18368.57% |
| 2021 Q1 | -4.09 Million AUD | 2.66% |
| 2021 Q2 | -8.19 Million AUD | -100.0% |
| 2020 Q2 | -5.31 Million AUD | -100.0% |
| 2020 Q4 | -4.21 Million AUD | -141.04% |
| 2020 Q3 | -1.74 Million AUD | 67.13% |
| 2020 Q1 | -2.65 Million AUD | 27.47% |
| 2020 FY | -9.53 Million AUD | 17.65% |
| 2019 FY | -11.57 Million AUD | -318.77% |
| 2019 Q2 | -7.9 Million AUD | -100.0% |
| 2019 Q3 | -1.58 Million AUD | 79.96% |
| 2019 Q1 | -3.95 Million AUD | -181.42% |
| 2019 Q4 | -3.66 Million AUD | -131.24% |
| 2018 Q3 | 4.85 Million AUD | 349.26% |
| 2018 Q1 | -1.94 Million AUD | -49.67% |
| 2018 Q4 | 4.85 Million AUD | 0.0% |
| 2018 FY | 5.29 Million AUD | 184.32% |
| 2018 Q2 | -1.94 Million AUD | 0.0% |
| 2017 Q1 | -1.73 Million AUD | 10.2% |
| 2017 FY | -6.27 Million AUD | 58.84% |
| 2017 Q3 | -1.3 Million AUD | 24.99% |
| 2017 Q2 | -1.73 Million AUD | 0.0% |
| 2017 Q4 | -1.3 Million AUD | 0.0% |
| 2016 Q2 | -4.07 Million AUD | 0.0% |
| 2016 FY | -15.24 Million AUD | 12.08% |
| 2016 Q1 | -4.07 Million AUD | 9.99% |
| 2016 Q4 | -1.93 Million AUD | 0.0% |
| 2016 Q3 | -1.93 Million AUD | 52.61% |
| 2015 FY | -17.34 Million AUD | -37.4% |
| 2015 Q4 | -4.52 Million AUD | 0.0% |
| 2015 Q1 | -3.26 Million AUD | -23.6% |
| 2015 Q2 | -3.26 Million AUD | 0.0% |
| 2015 Q3 | -4.52 Million AUD | -38.91% |
| 2014 Q3 | -2.63 Million AUD | -18.67% |
| 2014 Q1 | -2.22 Million AUD | -19.94% |
| 2014 Q4 | -2.63 Million AUD | 0.0% |
| 2014 FY | -12.62 Million AUD | -33.57% |
| 2014 Q2 | -2.22 Million AUD | 0.0% |
| 2013 Q3 | -1.85 Million AUD | -27.43% |
| 2013 FY | -9.44 Million AUD | 0.3% |
| 2013 Q2 | -1.45 Million AUD | 0.0% |
| 2013 Q1 | -1.45 Million AUD | 0.0% |
| 2013 Q4 | -1.85 Million AUD | 0.0% |
| 2012 FY | -9.47 Million AUD | -100.18% |
| 2011 FY | -4.73 Million AUD | 5.09% |
| 2010 FY | -4.98 Million AUD | -3904.59% |
| 2009 FY | 131.13 Thousand AUD | 101.39% |
| 2008 FY | -9.43 Million AUD | 21.98% |
| 2007 FY | -12.09 Million AUD | 0.71% |
| 2006 FY | -12.17 Million AUD | -7.87% |
| 2005 FY | -11.28 Million AUD | -60.84% |
| 2004 FY | -7.01 Million AUD | -402.28% |
| 2003 FY | 2.32 Million AUD | 45.47% |
| 2002 FY | 1.59 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | 13833.599% |
| Skye Bioscience, Inc. | -13.67 Million USD | 1361.677% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | -110.739% |
| Nascent Biotech, Inc. | -2.22 Million USD | 7835.577% |
| Qrons Inc. | -643.67 Thousand USD | 26898.223% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 2317.44% |
| CSL Limited | 3.7 Billion USD | 95.341% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 1066.515% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 3519.458% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 25210.124% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 410.755% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 41616.9% |
| Rebus Holdings, Inc. | -664 Thousand USD | 26078.012% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 13016.729% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 44378.05% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 1186.937% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 340.289% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -3409.677% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 66006.33% |
| SQZ Biotechnologies Company | -75.82 Million USD | 327.49% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 6151.345% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 11329.72% |
| Mesoblast Limited | -84.14 Million USD | 304.991% |
| Marizyme, Inc. | -34.08 Million USD | 606.048% |
| Genus plc | 6.4 Million USD | -2595.219% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | -1670.539% |
| Pharming Group N.V. | -4.87 Million USD | 3635.043% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 8783.404% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 18620.26% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 2165.796% |
| ContraFect Corporation | -56.88 Million USD | 403.212% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 3887.143% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 12403.503% |
| IMV Inc. | -38.67 Million USD | 546.049% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 6370.596% |
| MultiCell Technologies, Inc. | -722.81 USD | 23864462.696% |
| ONE Bio Corp. | 13.68 Million USD | -1160.778% |
| Accustem Sciences Inc. | -3.74 Million USD | 4704.237% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 392.412% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 35808.46% |
| Q BioMed Inc. | -3.44 Million USD | 5106.188% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -4772.712% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 6664.893% |
| Biomind Labs Inc. | -1 Million USD | 17185.33% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 413.783% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 6045.506% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 2694.669% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 9352.133% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 576001.442% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 9025.443% |
| GB Sciences, Inc. | -1.42 Million USD | 12243.112% |
| Alpha Cognition Inc. | -9.7 Million USD | 1877.262% |
| HST Global, Inc. | -140.9 Thousand USD | 122516.913% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 15434.081% |
| Halberd Corporation | -75.05 Thousand USD | 229938.774% |
| Enzolytics Inc. | -2.14 Million USD | 8127.457% |
| Agentix Corp. | -1.37 Million USD | 12674.685% |
| Resverlogix Corp. | -12.74 Million USD | 1453.0% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 5544.415% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -425.04 Million USD | 140.582% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 16622.414% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 6008.454% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 11021.8% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 5165.934% |
| AVAX Technologies, Inc. | 6.69 Million USD | -2477.276% |
| Zenith Capital Corp. | -8.94 Million USD | 2028.816% |
| Genscript Biotech Corporation | -415.79 Million USD | 141.486% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 990249.819% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 7125.325% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 100673.997% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 8704.235% |
| Kadimastem Ltd | -3.04 Million USD | 5773.678% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 17628.934% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 95145.872% |
| LadRx Corporation | -3.82 Million USD | 4611.268% |
| Cell Source, Inc. | -4.32 Million USD | 4087.982% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 25210.124% |
| NovAccess Global Inc. | -2.46 Million USD | 7092.735% |
| Affymax, Inc. | -15.04 Million USD | 1246.444% |
| Itoco Inc. | -919.14 Thousand USD | 18866.891% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 4169.777% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 15515.013% |
| Mobile Lads Corp. | -554.55 Thousand USD | 31205.22% |
| CytoDyn Inc. | -18.05 Million USD | 1055.222% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 685415.852% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 78478.575% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 30644.887% |
| SYBLEU INC | -149.18 Thousand USD | 115728.1% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 9596.895% |
| International Stem Cell Corporation | -663 Thousand USD | 26117.195% |
| Bioxytran, Inc. | -3.82 Million USD | 4615.376% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 327786.17% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 848153.097% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 575.636% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 10760.939% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 23541.94% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 5644.648% |
| Neutra Corp. | -229.48 Thousand USD | 75265.37% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 1083.488% |
| PureTech Health plc | -146.19 Million USD | 217.986% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 902.629% |
| IXICO plc | -1.43 Million USD | 12103.758% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 1917.448% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 241.614% |
| CSL Limited | 3.81 Billion USD | 95.475% |
| Cellectis S.A. | -108.85 Million USD | 258.459% |